Literature DB >> 12594241

Gene expression profile of serial samples of transformed B-cell lymphomas.

Sven de Vos1, Wolf-Karsten Hofmann, Thomas M Grogan, Utz Krug, Mathew Schrage, Thomas P Miller, Jonathan G Braun, William Wachsman, H Phillip Koeffler, Jonathan W Said.   

Abstract

Follicular lymphoma (FL) is characterized by a continuous rate of relapse and transformation to a high-grade lymphoma, usually diffuse large B-cell lymphoma (DLBCL), associated with a dismal prognosis and a poor response to conventional chemotherapy. The progression of indolent to aggressive FL is accompanied by the successive accumulation of recurrent chromosomal defects, but the resultant alterations of gene expression are largely unknown. To expand the understanding of the pathogenesis of FL transformation, we initially performed oligonucleotide microarray analyses using Affymetrix HuFL chips on five cases with matched snap-frozen lymph nodes before and after transformation. Expression data were analyzed using the Affymetrix Microarray Suite 4.0 and Genespring 4.0. Thirty-six genes with increased expression and 66 genes with decreased expression associated with transformation were identified and functionally classified. The expression of differentially expressed genes was confirmed by real-time quantitative RT-PCR (QRT-PCR) using a total of seven matched pairs and an additional five FL and five unrelated DLBCL. In addition, selected genes were further analyzed by QRT-PCR or immunohistochemistry using a large, unrelated series of FL (grades 1 to 3) as well as transformed and de novo DLBCL (total of 51 samples). The microarray results correlated with the protein expression data obtained from samples at the time of initial diagnosis and transformation. Furthermore, the expression of 25 candidate genes was evaluated by QRT-PCR with a 78% confirmation rate. Some of the identified genes, such as nucleobindin, interferon regulatory factor 4, and tissue inhibitor of metalloproteinases 1, are already known to be associated with high-grade non-Hodgkin's lymphoma. Novel candidate genes with confirmed increased and decreased expression in transformed DLBCL include ABL2 and NEK2, and PDCD1 and VDUP1, respectively. In summary, this study shows that transformation of FL to DLBCL is associated with a distinct set of differentially expressed genes of potential functional importance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594241     DOI: 10.1097/01.lab.0000053913.85892.e9

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  31 in total

1.  Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.

Authors:  Guillaume Jacquemin; Virginie Granci; Anne Sophie Gallouet; Najoua Lalaoui; Aymeric Morlé; Elisabetta Iessi; Alexandre Morizot; Carmen Garrido; Thierry Guillaudeux; Olivier Micheau
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.

Authors:  Andrew J Davies; Andreas Rosenwald; George Wright; Abigail Lee; Kim W Last; Dennis D Weisenburger; Wing C Chan; Jan Delabie; Rita M Braziel; Elias Campo; Randy D Gascoyne; Elaine S Jaffe; Konrad Muller-Hermelink; German Ott; Maria Calaminici; Andrew J Norton; Lindsey K Goff; Jude Fitzgibbon; Louis M Staudt; T Andrew Lister
Journal:  Br J Haematol       Date:  2007-01       Impact factor: 6.998

3.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

Authors:  Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; William T Bellamy; Maria Iannone; Daniel O Persky; Michael Leblanc; Richard I Fisher; Thomas P Miller
Journal:  Leuk Lymphoma       Date:  2009-05

4.  A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.

Authors:  Margaret E Tome; David B F Johnson; Lisa M Rimsza; Robin A Roberts; Thomas M Grogan; Thomas P Miller; Larry W Oberley; Margaret M Briehl
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

Review 5.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

6.  High expression of NEK2 promotes gastric cancer progression via activating AKT signaling.

Authors:  Hao Wan; Lin Xu; Huangbin Zhang; Feixiang Wu; Weiqiang Zeng; Taiyuan Li
Journal:  J Physiol Biochem       Date:  2020-11-17       Impact factor: 4.158

7.  Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal.

Authors:  Guikai Wu; Xiao-Long Qiu; Longen Zhou; Jiewen Zhu; Richard Chamberlin; Johnson Lau; Phang-Lang Chen; Wen-Hwa Lee
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

8.  A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients.

Authors:  Andrew J Gentles; Ash A Alizadeh; Su-In Lee; June H Myklebust; Catherine M Shachaf; Babak Shahbaba; Ronald Levy; Daphne Koller; Sylvia K Plevritis
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

9.  Insights into the conformational variability and regulation of human Nek2 kinase.

Authors:  Isaac Westwood; Donna-Marie Cheary; Joanne E Baxter; Mark W Richards; Rob L M van Montfort; Andrew M Fry; Richard Bayliss
Journal:  J Mol Biol       Date:  2008-12-24       Impact factor: 5.469

10.  Early over expression of messenger RNA for multiple genes, including insulin, in the Pancreatic Lymph Nodes of NOD mice is associated with Islet Autoimmunity.

Authors:  Béatrice Regnault; José Osorio Y Fortea; Dongmei Miao; George Eisenbarth; Evie Melanitou
Journal:  BMC Med Genomics       Date:  2009-10-02       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.